Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Terrance Mcguire sold 65,359 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73. Following the sale, the director now directly owns 4,012,320 shares of the company's stock, valued at $1,885,790.40. This represents a 1.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Terrance Mcguire also recently made the following trade(s):
IVVD stock traded down $0.10 during trading on Monday, reaching $0.45. The stock had a trading volume of 1,228,420 shares, compared to its average volume of 651,886. The firm has a fifty day moving average price of $0.82 and a 200 day moving average price of $1.05. The company has a market capitalization of $53.89 million, a P/E ratio of -0.23 and a beta of 0.53. Invivyd, Inc. has a 1-year low of $0.45 and a 1-year high of $5.20.
A number of research firms recently issued reports on IVVD. Morgan Stanley dropped their target price on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a research report on Wednesday, November 20th. HC Wainwright cut their price objective on Invivyd from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised Invivyd to a "strong-buy" rating in a research report on Wednesday, October 30th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Invivyd in a research note on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $7.89.
Check Out Our Latest Stock Report on Invivyd
Several institutional investors have recently modified their holdings of IVVD. State Street Corp grew its stake in Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company's stock valued at $1,039,000 after purchasing an additional 35,904 shares in the last quarter. Marshall Wace LLP grew its position in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company's stock worth $866,000 after buying an additional 31,992 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Invivyd by 232.0% in the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company's stock worth $745,000 after buying an additional 474,301 shares during the last quarter. Duquesne Family Office LLC acquired a new stake in Invivyd in the second quarter valued at $629,000. Finally, Renaissance Technologies LLC bought a new position in Invivyd during the 2nd quarter valued at $421,000. Institutional investors and hedge funds own 70.36% of the company's stock.
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.